Azithromycin for Prevention of Bronchopulmonary Dysplasia and Other Neonatal Adverse Outcomes in Preterm Infants: An Updated Systematic Review and Meta-Analysis
Neonatology · 2025
DOI: 10.1159/000547537 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Neonatology, 2025. Verfasst von Meghna Joseph und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Medical College Thiruvananthapuram, Thiruvananthapuram, India. Hauptthemen laut MEDLINE: Bronchopulmonary Dysplasia, Azithromycin, Anti-Bacterial Agents. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Neonatologie
Abstract (Originalsprache)
Introduction
Azithromycin, with its antimicrobial and anti-inflammatory properties, has been explored as a potential option for preventing bronchopulmonary dysplasia (BPD) in preterm infants.
Objective
We performed a meta-analysis of randomized controlled trials (RCTs) comparing azithromycin with placebo for the prevention of BPD in preterm infants.
Methods
PubMed, Scopus, ClinicalTrials.gov, and Cochrane Central databases were searched for studies comparing azithromycin versus placebo in preterm infants. Outcomes of interest included the composite of BPD and death, BPD, death, grade 2 or higher necrotizing enterocolitis (NEC), grade 3 or 4 intraventricular hemorrhage (IVH), retinopathy of prematurity (RoP), duration of mechanical ventilation, and postnatal corticosteroid requirement. Random-effects model was used to generate risk ratio (RR), mean difference (MD), and 95% confidence interval (CI) (CRD42024558752).
Results
The meta-analysis included 6 RCTs including 1,360 infants (azithromycin n = 680, 50%). The composite of BPD or death (RR: 0.95; 95% CI: 0.83–1.10; p = 0.53; I2 = 50.2%), BPD (RR: 0.98; 95% CI: 0.83–1.15; p = 0.77; I2 = 38.1%), death (RR: 0.88; 95% CI: 0.66–1.19; p = 0.41; I2 = 0%), NEC (RR: 0.94; 95% CI: 0.69–1.26; p = 0.67; I2 = 0%), IVH (RR: 1.22; 95% CI: 0.89–1.68; p = 0.22; I2 = 3.5%), RoP (RR: 1.35; 95% CI: 0.43–4.28; p = 0.61; I2 = 76.3%), duration of mechanical ventilation (MD: 0.13; 95% CI: −1.35 to 1.60; p = 0.87; I2 = 0%), and postnatal corticosteroid requirement (RR: 0.84; 95% CI: 0.64–1.08; p = 0.18; I2 = 34.5%) were similar between the groups.
Conclusion
In preterm infants, azithromycin did not significantly change the risk of adverse clinical outcomes compared with placebo.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Medical College Thiruvananthapuram, Thiruvananthapuram, India.
- Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
- Departament of Medicine, Barão de Mauá University Center, Ribeirão Preto, São Paulo, Brazil.
- Department of Medicine, University of Massachusetts - Baystate Medical Center, Springfield, Massachusetts, USA, cezenna349@gmail.com.
Zitieren
APA
Joseph, M., Murali Krishna, M., Karlinski Vizentin, V., Provinciatto, H., & Ezenna, C. (2025). Azithromycin for Prevention of Bronchopulmonary Dysplasia and Other Neonatal Adverse Outcomes in Preterm Infants: An Updated Systematic Review and Meta-Analysis. Neonatology. https://doi.org/10.1159/000547537
Vancouver
Joseph M, Murali Krishna M, Karlinski Vizentin V, Provinciatto H, Ezenna C. Azithromycin for Prevention of Bronchopulmonary Dysplasia and Other Neonatal Adverse Outcomes in Preterm Infants: An Updated Systematic Review and Meta-Analysis. Neonatology. 2025. doi:10.1159/000547537
BibTeX
@article{Joseph2025,
author = {Joseph, Meghna and Murali Krishna, Mrinal and Karlinski Vizentin, Vanessa and Provinciatto, Henrique and Ezenna, Chidubem},
title = {Azithromycin for Prevention of Bronchopulmonary Dysplasia and Other Neonatal Adverse Outcomes in Preterm Infants: An Updated Systematic Review and Meta-Analysis},
journal = {Neonatology},
year = {2025},
doi = {10.1159/000547537}
}
EUVIMED